We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite gain in recent years, venture funding for pharmaceutical innovation still lags behind prerecession levels, according to a new BIO report that also tracked a move away from developing novel therapies in favor of improving on existing ones. Read More
The Indian government is planning to relaunch a program that would sell hundreds of quality generic drugs at low cost under its own label, Jan Aushadhi. Read More
The court ruled that a brand drugmaker’s payment to settle an infringement case that delays generic competition can support a pay-for-delay claim. Read More
The FDA is creating a simple, one-step process for physicians to gain access to experimental drugs for patients facing terminal, untreatable conditions. Read More
Colorado lawmakers have introduced a biosimilar substitution bill that closely mirrors at least one aspect of compromise language unveiled by industry leaders in December — elimination of prescriber notification in favor of entering a switch into an electronic database. Read More